Details
Stereochemistry | RACEMIC |
Molecular Formula | C17H26ClN3O3 |
Molecular Weight | 355.86 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN(CC)CCNC(=O)C1=C(OC(C)C(C)=O)C=C(N)C(Cl)=C1
InChI
InChIKey=ZYOJXUNLLOBURP-UHFFFAOYSA-N
InChI=1S/C17H26ClN3O3/c1-5-21(6-2)8-7-20-17(23)13-9-14(18)15(19)10-16(13)24-12(4)11(3)22/h9-10,12H,5-8,19H2,1-4H3,(H,20,23)
Batanopride, previously known as BMY-25801, a 5-hydroxytryptamine 3 receptor antagonist, was studied against emesis for cancer patients that were treated by chemotherapy procedure. Batanopride had the dose-limiting side effects including hypotension and long QT syndrome that is why any further experiments for its medical application were discontinued.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
BMY-25801, an antiemetic agent free of D2-dopamine receptor antagonist properties. | 1988 Mar |
|
Dose-limiting hypotension with the 5-HT3-antagonist batanopride (BMY-25801). | 1991 Feb |
|
A randomized, double-blinded study comparing six doses of batanopride (BMY-25801) with methylprednisolone in patients receiving moderately emetogenic chemotherapy. | 1991 Oct |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1742224
six patient groups each received a single intravenous dose of batanopride ranging from 0.2 to 6.0 mg/kg
Route of Administration:
Intravenous
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C267
Created by
admin on Fri Dec 15 16:15:32 GMT 2023 , Edited by admin on Fri Dec 15 16:15:32 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID20869373
Created by
admin on Fri Dec 15 16:15:32 GMT 2023 , Edited by admin on Fri Dec 15 16:15:32 GMT 2023
|
PRIMARY | |||
|
6420
Created by
admin on Fri Dec 15 16:15:32 GMT 2023 , Edited by admin on Fri Dec 15 16:15:32 GMT 2023
|
PRIMARY | |||
|
SUB06108MIG
Created by
admin on Fri Dec 15 16:15:32 GMT 2023 , Edited by admin on Fri Dec 15 16:15:32 GMT 2023
|
PRIMARY | |||
|
BATANOPRIDE
Created by
admin on Fri Dec 15 16:15:32 GMT 2023 , Edited by admin on Fri Dec 15 16:15:32 GMT 2023
|
PRIMARY | |||
|
C060190
Created by
admin on Fri Dec 15 16:15:32 GMT 2023 , Edited by admin on Fri Dec 15 16:15:32 GMT 2023
|
PRIMARY | |||
|
100000088431
Created by
admin on Fri Dec 15 16:15:32 GMT 2023 , Edited by admin on Fri Dec 15 16:15:32 GMT 2023
|
PRIMARY | |||
|
59692
Created by
admin on Fri Dec 15 16:15:32 GMT 2023 , Edited by admin on Fri Dec 15 16:15:32 GMT 2023
|
PRIMARY | |||
|
C1021
Created by
admin on Fri Dec 15 16:15:32 GMT 2023 , Edited by admin on Fri Dec 15 16:15:32 GMT 2023
|
PRIMARY | |||
|
1AT99K728N
Created by
admin on Fri Dec 15 16:15:32 GMT 2023 , Edited by admin on Fri Dec 15 16:15:32 GMT 2023
|
PRIMARY | |||
|
CHEMBL38594
Created by
admin on Fri Dec 15 16:15:32 GMT 2023 , Edited by admin on Fri Dec 15 16:15:32 GMT 2023
|
PRIMARY | |||
|
102670-46-2
Created by
admin on Fri Dec 15 16:15:32 GMT 2023 , Edited by admin on Fri Dec 15 16:15:32 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE (PARENT)
SALT/SOLVATE (PARENT)